Want to see TSE:GLOW full AI Analyst Report?
Top Page
Glow LifeTech
(GLOW)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.04
▼(-28.33% Downside)
Action:Reiterated
Date:05/27/26
The score is primarily constrained by ongoing losses and negative free cash flow despite improving results, which keeps financial risk elevated. Technical signals are mixed with a weak longer-term trend, and valuation is pressured by an extremely high P/E with no dividend support.
Positive Factors
Strong Revenue Growth
Sustained, material revenue acceleration indicates improving product-market fit and demand traction. Over the next 2-6 months continued top-line growth can improve operating leverage, reduce per-unit costs, and give management room to prioritize path-to-profitability rather than near-term financing needs.
Negative Factors
Negative Operating Cash Flow
Ongoing negative operating cash flow shows the core business still consumes cash, forcing reliance on external financing or reserves. Over 2-6 months this elevates dilution or refinancing risk, constrains strategic investments, and limits ability to scale without fresh capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained, material revenue acceleration indicates improving product-market fit and demand traction. Over the next 2-6 months continued top-line growth can improve operating leverage, reduce per-unit costs, and give management room to prioritize path-to-profitability rather than near-term financing needs.
Read all positive factors
Glow LifeTech (GLOW) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.66M
Dividend YieldN/A
Average Volume (3M)266.05K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth86.40%
EPS Growth84.50%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding192,435,550
10 Day Avg. Volume165,602
30 Day Avg. Volume266,047
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.82
Price to Sales (P/S)5.04
P/FCF Ratio-87.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Glow LifeTech Business Overview & Revenue Model
Company Description
Glow Lifetech Corp. is a biotechnology enterprise based in North America, dedicated to the development and marketing of nutraceutical and cannabinoid-derived products. The company is actively commercializing two core technologies: MyCell Enhanced ...
Glow LifeTech Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
29
Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.05M | 836.19K | 43.93K | 0.00 | 0.00 |
| Gross Profit | 346.11K | 591.00K | -759.18K | -263.26K | -43.39K |
| EBITDA | -471.01K | -1.24M | -1.31M | -1.92M | -4.59M |
| Net Income | -617.86K | -2.66M | -1.59M | -2.24M | -11.31M |
Balance Sheet | |||||
| Total Assets | 3.92M | 3.72M | 1.91M | 2.31M | 3.76M |
| Cash, Cash Equivalents and Short-Term Investments | 1.37M | 1.29M | 34.00 | 75.19K | 746.02K |
| Total Debt | 56.19K | 404.08K | 171.75K | 147.36K | 39.93K |
| Total Liabilities | 1.21M | 1.15M | 2.35M | 1.14M | 328.03K |
| Stockholders Equity | 2.71M | 2.57M | -433.12K | 1.16M | 3.44M |
Cash Flow | |||||
| Free Cash Flow | -118.20K | -1.36M | -490.86K | -1.36M | -3.62M |
| Operating Cash Flow | -15.03K | -1.35M | -417.26K | -1.30M | -3.18M |
| Investing Cash Flow | -102.18K | 16.70K | -60.91K | 18.31K | -541.41K |
| Financing Cash Flow | 191.39K | 2.62M | 445.01K | 491.44K | 4.59M |
Glow LifeTech Technical Analysis
Negative
0.06
Price Trends
0.05
Negative
0.05
Negative
0.05
Negative
Market Momentum
>-0.01
Negative
44.45
Neutral
-100.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.45 is Neutral, neither overbought nor oversold. The STOCH value of -100.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLOW.
Glow LifeTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$15.79M | -9.80 | -78.88% | ― | 125.00% | 25.37% | |
42 Neutral | C$8.66M | -19.57 | -95.68% | ― | 86.40% | 84.50% | |
42 Neutral | C$8.49M | -0.37 | -13.16% | ― | -13.12% | 60.90% | |
41 Neutral | C$5.13M | -1.98 | ― | ― | ― | ― | |
38 Underperform | C$8.97M | -5.00 | 21.59% | ― | ― | -36.36% |
* Healthcare Sector Average
TSE:GLOW
Glow LifeTech
0.05
>-0.01
-10.00%
TSE:CSCI
COSCIENS Biopharma
8.00
-9.40
-54.02%
TSE:KNE
Kane Biotech
0.03
-0.02
-37.50%
TSE:QPT
Quest Pharmatech
0.02
-0.02
-50.00%
TSE:PREV
PreveCeutical Medical
0.02
-0.03
-62.50%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.15
0.05
50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.